Anti-Human C3b/iC3b Monoclonal Antibody (clone 3E7) -10 mg (CAT#: CB-P427-AB) Datasheet

Antibody

The monoclonal antibody 3E7 recognizes human complement C3b/iC3b and blocks the activation of other pathways (AP). The complement system plays an important role in both innate and adaptive immune responses, and can produce inflammatory and protective responses to pathogen attacks before the adaptive response occurs. There are three ways to activate complement. The classical pathway is triggered by immune complexes. Surface-bound mannan-bound lectin pathways; and all surfaces that are not specifically protected. Each produces C3 convertase, a serine protease that cleaves the central complement protein C3 and produces the main cleavage fragment C3b. C3 and C5 invertases are enzyme complexes that initiate and amplify the activity of the complement pathway and ultimately produce cytolytic MAC. After activating C3, two fragments will be generated. The smaller anaphylactoxin C3a and the larger short-lived C3b. The latter is highly reactive and can be combined with complement activating particles or immune complexes. Unlike the classic approach, AP is in a continuous activation state. AP plays an important role in tissue damage and inflammation associated with certain autoimmune diseases and ischemia-reperfusion injury. More and more evidences show that blocking AP activation can prevent or reduce certain diseases and maintain the host defense capabilities provided by CP and LP. The deposition of C3b on the cell surface can disrupt cell conditioning. Cell-bound C3b can be degraded into an inactive form, iC3b, and then degraded into C3dg. Antibody 3E7 shows enhanced specificity for C3b(i) attached to the cell surface, and can bind to cells conditioned by C3b(i) in whole blood. This antibody blocks AP based on its ability to prevent the deposition of C3b on the surface of various AP activators, and also inhibits AP-promoted lysis of rabbit red blood cells, as used in the standard AP50 test. Clone 3E7 competes with factors B and H for binding C3b opsonized substrates. The use of 3E7 has been shown to enhance the immunotherapeutic effect of rituximab. CP is not affected or enhanced by this antibody.

Infectious diseases, Nephrology